Want to see SCNI full AI Analyst Report?
SCNI Stock Chart & Stats
$0.23
-$0.02(-6.92%)
At close: 4:00 PM EDT
$0.23
-$0.02(-6.92%)
Day’s Range― - ―
52-Week Range$2.14 - $17.20
Previous CloseN/A
Volume35.26K
Average Volume (3M)101.31K
Market Cap
$1.08M
Enterprise Value$8.17
Total Cash (Recent Filing)$3.11M
Total Debt (Recent Filing)$3.50M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3837.20
Shares Outstanding3,959,792
10 Day Avg. Volume127,573
30 Day Avg. Volume101,310
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.21
Price to Sales (P/S)1.27
P/FCF Ratio-0.27
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CDMO Platform ExpansionThe acquired Yavne facility and Recipharm collaboration expand Scinai’s manufacturing capacity and service range. This can diversify revenue beyond drug development and create a more durable commercial platform.
Improved CapitalizationLower leverage and a stronger equity base provide more financial flexibility than in earlier stressed periods. Although losses remain, improved capitalization may support continued operations and investment in the pipeline.
Pipeline And Funding DevelopmentProgress across the NanoAb and PC111 programs, supported by grant applications and research collaborations, strengthens the company’s long-term innovation base. Non-dilutive funding could help advance assets while limiting financing pressure.
Bears Say
Persistent Cash BurnContinued operating and free cash outflows mean Scinai is not yet self-funding. Unless revenue scales or costs decline, the company may require additional external capital, creating ongoing financial and execution risk.
Weak Profitability And Limited ScaleRevenue remains small relative to the development-oriented cost base, and negative gross profit indicates limited current operating leverage. Sustainable profitability depends on significant commercialization growth or structural cost reductions.
Listing And Dilution RiskThe ADS restructuring highlights continuing minimum-bid and listing risks, while expanded share authorization increases future financing flexibility. Any capital raise could dilute existing holders and add pressure to the investment case.
Scinai Immunotherapeutics News
SCNI FAQ
What was Scinai Immunotherapeutics’s price range in the past 12 months?
Scinai Immunotherapeutics lowest stock price was $2.14 and its highest was $17.20 in the past 12 months.
What is Scinai Immunotherapeutics’s market cap?
Scinai Immunotherapeutics’s market cap is $1.08M.
When is Scinai Immunotherapeutics’s upcoming earnings report date?
Scinai Immunotherapeutics’s upcoming earnings report date is Dec 02, 2026 which is in 102 days.
How were Scinai Immunotherapeutics’s earnings last quarter?
Currently, no data Available
Is Scinai Immunotherapeutics overvalued?
According to Wall Street analysts Scinai Immunotherapeutics’s price is currently Overvalued.
Does Scinai Immunotherapeutics pay dividends?
Scinai Immunotherapeutics does not currently pay dividends.
What is Scinai Immunotherapeutics’s EPS estimate?
Scinai Immunotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics has 3,959,792 shares outstanding.
What happened to Scinai Immunotherapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Scinai Immunotherapeutics?
Currently, no hedge funds are holding shares in SCNI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
Technical Analysis
Ownership Overview
― Insiders
―
Mutual Funds
0.37% Other Institutional Investors
99.63% Public Companies and
Individual Investors